Cervical & ovarian cancer specialist Dr John Chia

Dr John Chia

Senior Consultant, Specialist in Medical Oncology

MBBS (S’pore), MRCP (UK), FAMS (Medical Oncology)


Dr John Chia graduated with double distinctions in Medicine and Surgery from the National University of Singapore in 1999, and obtained his Membership of the Royal College of Physicians in Edinburgh in 2002. Early on in his career, he was actively engaged with the then nascent field of immunotherapy for solid cancers, and heavily involved with the leadership or development of 7 immunotherapy clinical trials in Singapore. Post Oncology Boards in 2008 and 2009, he undertook fellowship training with Professor Malcom Brenner – in the field of Immunotherapy for Solid Tumours – namely in the development of dendritic cancer vaccines, adoptive T cell therapy, and immune biomarker monitoring for cancers. In 2011 and 2012, he completed a second fellowship with Professor Stan Kaye at The Royal Marsden Hospital London for the Advanced Management of Gynaecological cancers.

Dr Chia is active in clinical trial research, and has developed numerous research protocols and trials for ovarian, cervical, colorectal, nasopharyngeal, and breast cancer. He has published widely in leading international journals, and holds numerous local and international research grants exceeding 10 million dollars – for research in immune check-point inhibitors, cancer vaccines, T cell therapy, Aspirin chemoprevention, and small molecule inhibitors for cancer. In 2010, he was awarded “Best Poster” for a tumour-specific cancer vaccine trial at the European Society of Medical Oncology, Milan (amongst several thousand submissions), and more recently “Best Poster Presentation” at ESMO Asia in 2017, for his clinical trial in aggressive ovarian cancer.

Dr Chia was the former Chief of the Gynaecology Oncology service in the Division of Medical Oncology, National Cancer Centre, and is Vice-President and founding board member of the Gynaecologic Cancer Group Singapore, and Adjunct Associate Professor at DUKE-NUS. He lectures widely, including in Japan, Korea, HK, China, UK – including plenary symposia lectures in Germany, Australia and ESMO Asia. Locally he has helped to write the Singapore ovarian and uterine cancer management guidelines (SCAN).

He is exco member of the Mt Eliz Novena Hospital medical board and the ex-chair of their Neoplasia committee. He is a member of the Parkway Independent Ethics committee since 2019, that oversees the review and approval of clinical trials, recruiting human subjects for novel therapies in the Parkways hospital system.

For more than 20 years, Dr Chia has run a busy clinical practice, managing complex Gynae-oncology. His sub-speciality interests include Ovarian, Endometrial, Cervical, Breast and Colorectal cancers – including the management of rare tumours – such as melanoma, uterine sarcomas, and germ cell tumours.

Area of Interest

Breast cancer

Gastrointestinal cancer

Gynaecological cancer

Lung cancer

Curie Oncology Locations

Farrer Park Medical Centre

Mount Elizabeth Novena Specialist Centre

Mount Elizabeth Medical Centre (Orchard)



Clinical Trials

No.Tumor TypeStageStudy TitlePrincipal InvestigatorDetailsStatus
1Lung CancerIVA Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung CancerDr Toh Chee Keong#NCT04262856Open
2Breast cancerIVA Randomized, multicentre, double-blind phase 3 study of SAR439859 plus palbociclib versus letrozole plus palbociclib for the treatment of ER(+), HER(-) breast cancer who have not received any prior systemic anti-cancer treatment for advanced diseaseDr Lynette Ngo#NCT04478266Open
3Hepatocellular carcinomaIVA Phase III, Randomized Double-blind, Placebo-controlled, Multicentre Study of Transarterial Chemoembolization (TACE) in Combination With either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma (EMERALD-1)Dr Choo Su Pin#NCT03778957

Emerald-1 Trial Patient Information
4Endometrial cancer IVA Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer(DUO-E)Dr Lynette Ngo#NCT04269200Open
5Gastric cancerIVA Randomized, Double-blinded, Multicenter, Phase III Clinical Study of HLX10 (Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection) Combined with Chemotherapy versus Placebo Combined with Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric CancerDr Choo Su Pin#NCT04139135Closed